세계의 나노의학 시장 보고서 : 나노분자 유형, 제품, 용도, 지역별(2024-2032년)

The global nanomedicine market size reached US$ 263.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 719.5 Billion by 2032, exhibiting a growth rate (CAGR) of 11.4% during 2024-2032.

Nanomedicine refers to specialized multi-functional drugs with programmable properties used for the treatment of diseases and repairing tissues at a molecular level. It involves the use of nanoparticles, nanotubes and nanodevices, such as imaging agents, nanorobots, biochips and polymer therapeutics, for the diagnosis, treatment and prevention of a disorder and analyzing the underlying pathophysiology. The nanoparticles include metal and metal oxides, liposomes and inorganic particles, which are used for transporting the drugs and targeting difficult to reach areas in the body. As a result, nanomedicine finds extensive applications for drug delivery, diagnostic imaging, vaccines, regenerative medicines and implants.

Nanomedicine Market Trends:

The increasing prevalence of chronic medical ailments across the globe is one of the key factors creating a positive outlook for the market. Nanomedicine is highly beneficial in the treatment of oncological, neurological, urological, infectious, ophthalmological, orthopedic, immunological and cardiovascular diseases. In line with this, shifting preference for personalized medicines is also contributing to the growth of the market. Additionally, various technological advancements in the nanoscale technologies for improved diagnostic procedures are acting as other growth-inducing factors. Pharmaceutical manufacturers are using nanorobotic systems and other novel solutions for the effective administration of nanomedicines. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities in the field of biotechnology, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global nanomedicine market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on nanomolecule type, product and application.

Breakup by Nanomolecule Type:

Nanoparticles

Metal and Metal Oxide Nanoparticles

Liposomes

Polymers and Polymer Drug Conjugates

Hydrogel Nanoparticles

Dendrimers

Inorganic Nanoparticles

Nanoshells

Nanotubes

Nanodevices

Breakup by Product:

Therapeutics

Regenerative Medicine

In-Vitro Diagnostics

In-Vivo Diagnostics

Vaccines

Breakup by Application:

Clinical Oncology

Infectious Diseases

Clinical Cardiology

Orthopedics

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arrowhead Pharmaceuticals Inc., General Electric Company, Luminex Corporation, Merck & Co. Inc., Nanobiotix, Novartis AG, Pfizer Inc., Sanofi SA and Starpharma Holdings Limited.

Key Questions Answered in This Report

• 1. How big is the global nanomedicine market?
• 2. What is the expected growth rate of the global nanomedicine market during 2024-2032?
• 3. What are the key factors driving the global nanomedicine market?
• 4. What has been the impact of COVID-19 on the global nanomedicine market?
• 5. What is the breakup of the global nanomedicine market based on the nanomolecule type?
• 6. What is the breakup of the global nanomedicine market based on the product?
• 7. What is the breakup of the global nanomedicine market based on the application?
• 8. What are the key regions in the global nanomedicine market?
• 9. Who are the key players/companies in the global nanomedicine market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Nanomedicine Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Nanomolecule Type

• 6.1 Nanoparticles
  • 6.1.1 Market Trends
  • 6.1.2 Major Types
    • 6.1.2.1 Metal and Metal Oxide Nanoparticles
    • 6.1.2.2 Liposomes
    • 6.1.2.3 Polymers and Polymer Drug Conjugates
    • 6.1.2.4 Hydrogel Nanoparticles
    • 6.1.2.5 Dendrimers
    • 6.1.2.6 Inorganic Nanoparticles
  • 6.1.3 Market Forecast
• 6.2 Nanoshells
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Nanotubes
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Nanodevices
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Product

• 7.1 Therapeutics
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Regenerative Medicine
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 In-Vitro Diagnostics
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 In-Vivo Diagnostics
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Vaccines
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by Application

• 8.1 Clinical Oncology
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Infectious Diseases
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Clinical Cardiology
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Orthopedics
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Others
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abbott Laboratories
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Arrowhead Pharmaceuticals Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 General Electric Company
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
  • 14.3.4 Luminex Corporation
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Merck & Co. Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Nanobiotix
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
  • 14.3.7 Novartis AG
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Pfizer Inc.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
    • 14.3.8.4 SWOT Analysis
  • 14.3.9 Sanofi SA
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Starpharma Holdings Limited
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials